FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany lub rozsiany nowotwór z mutacją genu FGFR3
- •Rak pęcherza moczowego zaawansowany lub rozsiany z mutacją genu FGFR3
- •Rak pęcherza moczowego wcześniej leczony lekiem erdafitynib
- •Mięsak pęcherza moczowego z mutacją genu FGFR3
- •Możliwość zmierzenia zmian nowotworowych lub stwierdzenia ich obecności
- •Ogólny stan zdrowia pacjenta na poziomie pozwalającym uczestniczyć w badaniu
✗ Disqualifies
- •Rak pierwotny mózgu
- •Przerzuty do mózgu, które nie były leczone lub są niekontrolowane
- •Problemy z rogówką oka lub zaburzenia siatkówki
- •Poważne skutki uboczne z poprzednich leczenia, które nie ustąpiły
- •Istotna choroba serca
- •Zaburzenia rytmu serca
- •Aktywna infekcja zakaźna organizmu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (82)
University of Arizona - Cancer Center
Tucson, United States
City of Hope
Duarte, United States
University of California, Los Angeles (UCLA) - Division of Hematology-Oncology
Los Angeles, United States
University of California - Irvine
Orange, United States
University of California (UC) Davis Comprehensive Cancer Center
Sacramento, United States
Stanford Medicine Cancer Center
Stanford, United States
Advent Health
Orlando, United States
Emory University Hospital
Atlanta, United States
The University of Chicago Medical Center (UCMC)
Chicago, United States
Indiana University (IU) Melvin and Bren Simon Cancer Center
Indianapolis, United States
Mary Bird Perkins Cancer Center
Baton Rouge, United States
Ochsner Clinic Foundation
New Orleans, United States
Johns Hopkins Kimmel Cancer Center
Baltimore, United States
Massachusetts General Hospital
Boston, United States
Barbara Ann Karmanos Cancer Institute
Detroit, United States
Washington University in St. Louis
St Louis, United States
New York University (NYU)
New York, United States
Weill Cornell Medicine
New York, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Columbia University
New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
University of Rochester - Wilmot Cancer Institute
Rochester, United States
Montefiore Medical Center
The Bronx, United States
University of North Carolina (UNC) - Chapel Hill
Chapel Hill, United States
University of Cincinnati Medical Center (UCMC)
Cincinnati, United States
The Ohio State University (OSU)
Columbus, United States
University of Oklahoma - Health Sciences Center
Oklahoma City, United States
Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute
Lancaster, United States
University of Pennsylvania
Philadelphia, United States
Thomas Jefferson University
Philadelphia, United States
Allegheny General Hospital
Pittsburgh, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
Carolina Urologic Research Center
Myrtle Beach, United States
Sarah Cannon and HCA Research Institute
Nashville, United States
Tennessee Oncology
Nashville, United States
Vanderbilt University Medical Center
Nashville, United States
University of Texas Southwestern
Dallas, United States
Texas Oncology, P.A
Dallas, United States
MD Anderson Cancer Center
Houston, United States
University of Utah
Salt Lake City, United States
University of Vermont Medical Center
Burlington, United States
St Vincent's Hospital
Darlinghurst, Australia
Calvary Mater Newcastle
Hunter Region, NSW, Australia
GenesisCare North Shore
St Leonards, Australia
Macquarie University
Sydney, Australia
Princess Margaret Hospital
Toronto, Canada
British Columbia Cancer Agency
Vancouver, Canada
Beijing Cancer hospital
Beijing, China
Beijing Hospital
Beijing, China
Sun Yat-Sen University- Cancer Center
Guangdong, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Zhejiang Provincial People's Hospital
Zhejiang, China
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
München, Germany
Universitaetsklinikum Tuebingen
Tübingen, Germany
Rabin Medical Center, Beilinson Hospital
Petah Tikva, Israel
Sheba Medical Center
Tel Litwinsky, Israel
IRCCS Ospedale San Raffaele
Milan, Italy
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Roma, Italy
National Cancer Center Hospital East
Chiba, Japan
Aichi Cancer Center Hospital
Nagoya, Japan
National Cancer Center Hospital
Tokyo, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
Erasmus MC
GE Rotterdam, Netherlands
Haukeland University Hospital
Bergen, Norway
Oslo University Hospital
Oslo, Norway
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, Spain
Fundacion MD Anderson International Espana
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, Spain
Hospital Universitario Marques De Valdecilla
Santander, Spain
The Christie NHS Foundation Trust
Manchester, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
Trial contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Physicians interested in becoming principal investigators please contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.